Provided by Tiger Trade Technology Pte. Ltd.

Tscan Therapeutics, Inc.

0.3145
-0.0030-0.94%
Post-market: 0.31450.00000.00%16:15 EDT
Volume:554.29K
Turnover:180.52K
Market Cap:21.32M
PE:-0.35
High:0.3450
Open:0.3222
Low:0.3145
Close:0.3175
52wk High:2.57
52wk Low:0.2902
Shares:67.78M
Float Shares:54.37M
Volume Ratio:0.87
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9000
EPS(LYR):-2.2805
ROE:-95.80%
ROA:-31.53%
PB:0.31
PE(LYR):-0.14

Loading ...

TScan Therapeutics Announces Executive Departures Amid Reorganization

TIPRANKS
·
1 hour ago

TScan Therapeutics Says CFO Jason Amello Steps Down in Reorganization

Reuters
·
1 hour ago

TScan Therapeutics Launches Executive Retention Incentive Program

TIPRANKS
·
Sep 11

TScan Rolls Out Retention Plan with $822,000 Cash Award for CEO Gavin MacBeath

Reuters
·
Sep 11

TScan Therapeutics, Inc. : H.c. Wainwright Cuts to Neutral from Buy

THOMSON REUTERS
·
Sep 08

TScan Therapeutics Cut to Hold from Buy by Needham

Dow Jones
·
Sep 03

TScan Therapeutics Inc : Needham Cuts to Hold from Buy

THOMSON REUTERS
·
Sep 03

U.S. Stocks on the MOVE-FuelCell, Gold Miners, NetApp

Reuters
·
Sep 03

TScan Therapeutics Inc : Wedbush Cuts to Neutral from Outperform; Cuts Target Price to $1 from $5

THOMSON REUTERS
·
Sep 02

TScan Therapeutics Restructures to Focus on Solid Tumors

TIPRANKS
·
Sep 02

TScan Therapeutics Falls After Pausing Cancer Trial

Reuters
·
Sep 02

TScan Therapeutics - Expects to Complete Strategic Reorganization by End of Q4 2026 - SEC Filing

THOMSON REUTERS
·
Sep 02

TScan Therapeutics - CEO Gavin Macbeath Assumes Principal Financial and Accounting Officer Duties as of Sept 2, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 02

TScan Therapeutics Inc - Expects to Incur About $4.1 Million in Employee-Related Costs, Consisting Primarily of Pay Continuation and Related Benefits

THOMSON REUTERS
·
Sep 02

TScan Therapeutics - Jason A. Amello, CFO, and Chrystal Louis, Cmo, Terminated Effective Sept 2, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 02

TScan Therapeutics Inc - Expects That Substantially All of Reorg Charges Will Result in Future Cash Expenditures

THOMSON REUTERS
·
Sep 02

TScan Therapeutics Cuts Workforce 75% in Reorganization to Focus on in Vivo Solid Tumor Cell Therapy

Reuters
·
Sep 02

TScan Therapeutics - Pauses Enrollment in Phase 3 Alloha-2 Study of Tsc-101 Due to Insufficient Capital

THOMSON REUTERS
·
Sep 02

TScan Therapeutics - to Share Preclinical Data Q1 2027, File Ind Q3 2027, Initiate Phase 1 Q4 2027

THOMSON REUTERS
·
Sep 02

TScan Therapeutics - to Reduce Workforce by About 75% and Extend Cash Runway into Q4 2027

THOMSON REUTERS
·
Sep 02